{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:23:41Z","timestamp":1778750621249,"version":"3.51.4"},"reference-count":47,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T00:00:00Z","timestamp":1628294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Key R&D Program of China","award":["2018YFA0800801"],"award-info":[{"award-number":["2018YFA0800801"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670714, No0.81970757"],"award-info":[{"award-number":["81670714, No0.81970757"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2020-I2M-C&T-B-016"],"award-info":[{"award-number":["2020-I2M-C&T-B-016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Sclerostin inhibits Wnt-\u03b2-catenin signaling, regulating bone formation. Circulating sclerostin was reported to be elevated in X-linked hypophosphatemia (XLH) patients, and sclerostin antibody (Scl-Ab) increased bone mass and normalized circulating phosphate in Hyp mice. However, circulating sclerostin levels in patients with acquired hypophosphatemia due to tumor-induced osteomalacia (TIO) are rarely reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study was designed to evaluate serum sclerostin levels in TIO patients compared with age- and sex-matched healthy controls and XLH patients to analyze correlations with bone mineral density (BMD) and laboratory parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This cross-sectional study determined serum sclerostin levels in 190 individuals, comprising 83 adult TIO patients, 83 adult healthy controls and 24 adult XLH patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TIO patients (43 male, 40 female) aged 44.3\u2005\u00b1\u20058.7 (mean \u00b1 SD) years had lower levels of circulating sclerostin than controls (94.2\u2005\u00b1\u200545.8 vs 108.4\u2005\u00b1\u200542.3 pg\/mL, P\u2005=\u20050.01), adjusted for age, gender, BMI, and diabetes rate. Sclerostin levels were positively associated with age (r =\u20050.238, P\u2005=\u20050.030). Male patients had higher sclerostin than female patients (104.7\u2005\u00b1\u200547.3 vs 83.0\u2005\u00b1\u200541.8 pg\/mL, P\u2005=\u20050.014). Sclerostin levels were positively associated with L1-4 BMD (r =\u20050.255, P\u2005=\u20050.028), femoral neck BMD (r =\u20050.242, P\u2005=\u20050.039), and serum calcium (r =\u20050.231, P\u2005=\u20050.043). Comparison of sclerostin levels in TIO patients (n\u2005=\u200524, age 35.9\u2005\u00b1\u20057.3 years) vs XLH patients vs healthy controls revealed significant differences (respectively, 68.4\u2005\u00b1\u200531.3, 132.0\u2005\u00b1\u200568.8, and 98.6\u2005\u00b1\u200541.1 pg\/mL, P\u2005&amp;lt;\u20050.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Circulating sclerostin was decreased in TIO patients but increased in XLH patients, possibly due to histological abnormality and bone mass.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab579","type":"journal-article","created":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T18:38:30Z","timestamp":1628361510000},"page":"e361-e371","source":"Crossref","is-referenced-by-count":3,"title":["Low Levels of Serum Sclerostin in Adult Patients With Tumor-Induced Osteomalacia Compared With X-linked Hypophosphatemia"],"prefix":"10.1210","volume":"107","author":[{"given":"Xiaolin","family":"Ni","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9524","authenticated-orcid":false,"given":"Yiyi","family":"Gong","sequence":"additional","affiliation":[{"name":"Central Research Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4434-3462","authenticated-orcid":false,"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5536","authenticated-orcid":false,"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,8,7]]},"reference":[{"issue":"2","key":"2021121823113095500_CIT0001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med."},{"issue":"5","key":"2021121823113095500_CIT0002","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet."},{"issue":"3","key":"2021121823113095500_CIT0003","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet."},{"issue":"6","key":"2021121823113095500_CIT0004","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2021121823113095500_CIT0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","article-title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice","volume":"25","author":"Kramer","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"16","key":"2021121823113095500_CIT0006","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2021121823113095500_CIT0007","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2021121823113095500_CIT0008","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.2188","article-title":"Bone matrix quality after sclerostin antibody treatment","volume":"29","author":"Ross","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2021121823113095500_CIT0009","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00223-019-00526-z","article-title":"Elevated bone remodeling markers of CTX and P1NP in addition to sclerostin in patients with X-linked hypophosphatemia: a cross-sectional controlled study","volume":"104","author":"Hansen","year":"2019","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"2021121823113095500_CIT0010","doi-asserted-by":"crossref","first-page":"E920","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating sclerostin in children and young adults with heritable bone disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"10189","key":"2021121823113095500_CIT0011","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"issue":"21","key":"2021121823113095500_CIT0012","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2021121823113095500_CIT0013","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.3923","article-title":"Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing hyp mice","volume":"35","author":"Carpenter","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2021121823113095500_CIT0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J."},{"issue":"3","key":"2021121823113095500_CIT0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","article-title":"Nonremission and recurrent tumor-induced osteomalacia: a retrospective study","volume":"35","author":"Li","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2021121823113095500_CIT0016","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0031-1275661","article-title":"Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia","volume":"119","author":"Kaji","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"9","key":"2021121823113095500_CIT0017","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","article-title":"Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature","volume":"27","author":"Jiang","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"7929","key":"2021121823113095500_CIT0018","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"2","author":"Walton","year":"1975","journal-title":"Lancet."},{"issue":"7","key":"2021121823113095500_CIT0019","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s00198-016-3543-5","article-title":"Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type","volume":"27","author":"El-Maouche","year":"2016","journal-title":"Osteoporos Int"},{"key":"2021121823113095500_CIT0020","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.2147\/CIA.S186199","article-title":"Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol","volume":"13","author":"Cheng","year":"2018","journal-title":"Clin Interv Aging."},{"key":"2021121823113095500_CIT0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.08.003","article-title":"High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke","volume":"253","author":"He","year":"2016","journal-title":"Atherosclerosis."},{"issue":"2","key":"2021121823113095500_CIT0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2021121823113095500_CIT0023","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fcell.2020.00057","article-title":"Sclerostin and its associations with bone metabolism markers and sex hormones in healthy community-dwelling elderly individuals and adolescents","volume":"8","author":"Xu","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"2021121823113095500_CIT0024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jc.2011-2186","article-title":"Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus","volume":"97","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021121823113095500_CIT0025","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women","volume":"26","author":"Ardawi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2021121823113095500_CIT0026","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jsbmb.2014.11.021","article-title":"Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass","volume":"148","author":"Ryan","year":"2015","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"2","key":"2021121823113095500_CIT0027","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bbrc.2011.12.048","article-title":"The sclerostin-bone protein interactome","volume":"417","author":"Devarajan-Ketha","year":"2012","journal-title":"Biochem Biophys Res Commun."},{"issue":"6","key":"2021121823113095500_CIT0028","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2021121823113095500_CIT0029","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr Rev."},{"issue":"12","key":"2021121823113095500_CIT0030","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1210\/jc.2011-0566","article-title":"Circulating sclerostin in disorders of parathyroid gland function","volume":"96","author":"Costa","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"13","key":"2021121823113095500_CIT0031","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"Faseb J."},{"issue":"6","key":"2021121823113095500_CIT0032","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/jbmr.3683","article-title":"DMP1 Ablation in the rabbit results in mineralization defects and abnormalities in haversian canal\/osteon microarchitecture","volume":"34","author":"Liu","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2021121823113095500_CIT0033","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","article-title":"Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23","volume":"52-54","author":"Ren","year":"2016","journal-title":"Matrix Biol."},{"issue":"6","key":"2021121823113095500_CIT0034","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"van Bezooijen","year":"2009","journal-title":"J Dent Res."},{"issue":"1","key":"2021121823113095500_CIT0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10067-020-05150-z","article-title":"Serum levels of leptin, osteopontin, and sclerostin in patients with and without knee osteoarthritis","volume":"40","author":"Min","year":"2021","journal-title":"Clin Rheumatol."},{"issue":"2","key":"2021121823113095500_CIT0036","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"2021121823113095500_CIT0037","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00198-017-3949-8","article-title":"Evaluation of bone mineral density and microarchitectural parameters by DXA and HR-pQCT in 37 children and adults with X-linked hypophosphatemic rickets","volume":"28","author":"Colares Neto","year":"2017","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021121823113095500_CIT0038","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00223-020-00755-7","article-title":"Clinical characteristics and bone features of autosomal recessive hypophosphatemic rickets type 1 in three Chinese families: report of five chinese cases and review of the literature","volume":"107","author":"Ni","year":"2020","journal-title":"Calcif Tissue Int."},{"issue":"8","key":"2021121823113095500_CIT0039","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00198-013-2286-9","article-title":"High bone mineral apparent density in children with X-linked hypophosphatemia","volume":"24","author":"Beck-Nielsen","year":"2013","journal-title":"Osteoporos Int"},{"issue":"5","key":"2021121823113095500_CIT0040","doi-asserted-by":"crossref","first-page":"E954","DOI":"10.1210\/jc.2012-4133","article-title":"Cortical and trabecular bone density in X-linked hypophosphatemic rickets","volume":"98","author":"Cheung","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021121823113095500_CIT0041","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2013the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","journal-title":"Osteoporos Int."},{"issue":"11","key":"2021121823113095500_CIT0042","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3390\/jcm9113439","article-title":"Anti-sclerostin antibodies in osteoporosis and other bone diseases","volume":"9","author":"Fabre","year":"2020","journal-title":"J Clin Med"},{"issue":"5","key":"2021121823113095500_CIT0043","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1210\/jc.2017-02762","article-title":"Negative association between sclerostin and INSL3 in isolated human osteocytes and in klinefelter syndrome: new hints for testis-bone crosstalk","volume":"103","author":"Di Nisio","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"key":"2021121823113095500_CIT0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.03.045","article-title":"Circulating Wnt inhibitory factor 1 levels are associated with development of cardiovascular disease","volume":"273","author":"Ress","year":"2018","journal-title":"Atherosclerosis."},{"key":"2021121823113095500_CIT0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bone.2016.10.012","article-title":"Sclerostin measurement in human disease: validity and current limitations","volume":"96","author":"Costa","year":"2017","journal-title":"Bone."},{"issue":"7","key":"2021121823113095500_CIT0046","doi-asserted-by":"crossref","first-page":"E1159","DOI":"10.1210\/jc.2011-0254","article-title":"Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays","volume":"96","author":"McNulty","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021121823113095500_CIT0047","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.3390\/jcm8122027","article-title":"Clinical inference of serum and bone sclerostin levels in patients with end-stage kidney disease","volume":"8","author":"Mar\u00e9","year":"2019","journal-title":"J Clin Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab579\/40257013\/dgab579.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e361\/41819179\/dgab579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/1\/e361\/41819179\/dgab579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:13:45Z","timestamp":1639869225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/1\/e361\/6345230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,7]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab579","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,7]]}}}